These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11270909)

  • 1. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis.
    Rausch JL; Hobby HM; Shendarkar N; Johnson ME; Li J
    J Clin Psychopharmacol; 2001 Apr; 21(2):139-42. PubMed ID: 11270909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.
    Bianchi M; Moser C; Lazzarini C; Vecchiato E; Crespi F
    Exp Brain Res; 2002 Mar; 143(2):191-7. PubMed ID: 11880895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.
    Suhara T; Takano A; Sudo Y; Ichimiya T; Inoue M; Yasuno F; Ikoma Y; Okubo Y
    Arch Gen Psychiatry; 2003 Apr; 60(4):386-91. PubMed ID: 12695316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome.
    Rausch JL; Johnson ME; Fei YJ; Li JQ; Shendarkar N; Hobby HM; Ganapathy V; Leibach FH
    Biol Psychiatry; 2002 May; 51(9):723-32. PubMed ID: 11983186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
    Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
    Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
    Marazziti D; Pfanner C; Palego L; Gemignani A; Milanfranchi A; Ravagli S; Lensi P; Presta S; Cassano GB
    Pharmacopsychiatry; 1997 Nov; 30(6):245-9. PubMed ID: 9442546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.
    Smeraldi E; Zanardi R; Benedetti F; Di Bella D; Perez J; Catalano M
    Mol Psychiatry; 1998 Nov; 3(6):508-11. PubMed ID: 9857976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine.
    Ito K; Yoshida K; Sato K; Takahashi H; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Psychiatry Res; 2002 Aug; 111(2-3):235-9. PubMed ID: 12374640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice.
    Montañez S; Owens WA; Gould GG; Murphy DL; Daws LC
    J Neurochem; 2003 Jul; 86(1):210-9. PubMed ID: 12807440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
    Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin.
    Narayan M; Anderson G; Cellar J; Mallison RT; Price LH; Nelson JC
    J Clin Psychopharmacol; 1998 Feb; 18(1):67-71. PubMed ID: 9472845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
    Zanardi R; Serretti A; Rossini D; Franchini L; Cusin C; Lattuada E; Dotoli D; Smeraldi E
    Biol Psychiatry; 2001 Sep; 50(5):323-30. PubMed ID: 11543734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders.
    Amitai M; Taler M; Carmel M; Michaelovsky E; Eilat T; Yablonski M; Orpaz N; Chen A; Apter A; Weizman A; Fennig S
    J Child Adolesc Psychopharmacol; 2016 Oct; 26(8):727-732. PubMed ID: 26771135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment.
    Takahashi H; Yoshida K; Ito K; Sato K; Kamata M; Higuchi H; Shimizu T; Ito K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K
    Eur Neuropsychopharmacol; 2002 Oct; 12(5):477-81. PubMed ID: 12208565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.
    Yoshida K; Ito K; Sato K; Takahashi H; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):383-6. PubMed ID: 11817517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.